Evidence map›Paper›PMID 25745863›Full record

ArticlePLoS neglected tropical diseases2015

Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.

Rajendra K Baharia, Rati Tandon, Tanuj Sharma, Manish K Suthar, Sanchita Das, Mohammad Imran Siddiqi, Jitendra Kumar Saxena, Shaym Sundar, Shyam Sunder, Anuradha Dube

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. GlSir2.1 ofHeliyon · 2019
    Article
  4. Frontiers in immunology · 2019
    Review
  5. The F1F3 Recombinant Chimera ofFrontiers in immunology · 2019
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rajendra K BahariaDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Rati TandonDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Tanuj SharmaDivision of Molecular and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
Manish K SutharDivision of Biochemistry, CSIR-Central Drug Research Institute, Lucknow, India.
Sanchita DasDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Mohammad Imran SiddiqiDivision of Molecular and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India.
Jitendra Kumar SaxenaDivision of Biochemistry, CSIR-Central Drug Research Institute, Lucknow, India.
Shaym Sundar
Shyam SunderDepartment of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Anuradha DubeDivision of Parasitology, CSIR-Central Drug Research Institute, Lucknow, India.
Central Drug Research Institute · INBanaras Hindu University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of a vaccine conferring long-lasting immunity remains a challenge against visceral leishmaniasis (VL). Immunoproteomic characterization of Leishmania donovani proteins led to the identification of a novel protein NAD+-dependent Silent Information regulatory-2 (SIR2 family or sirtuin) protein (LdSir2RP) as one of the potent immunostimulatory proteins. Proteins of the SIR2 family are characterized by a conserved catalytic domain that exerts unique NAD-dependent deacetylase activity. In the present study, an immunobiochemical characterization of LdSir2RP and further evaluation of its immunogenicity and prophylactic potential was done to assess for its possible involvement as a vaccine candidate against leishmaniasis. METHODOLOGY/PRINCIPAL

findingsLdSir2RP was successfully cloned, expressed and purified. The gene was present as a monomeric protein of ~45 kDa and further established by the crosslinking experiment. rLdSir2RP shown cytosolic localization in L. donovani and demonstrating NAD+-dependent deacetylase activity. Bioinformatic analysis also confirmed that LdSir2RP protein has NAD binding domain. The rLdSir2RP was further assessed for its cellular response by lymphoproliferative assay and cytokine ELISA in cured Leishmania patients and hamsters (Mesocricetus auratus) in comparison to soluble Leishmania antigen and it was observed to stimulate the production of IFN-γ, IL-12 and TNF-α significantly but not the IL-4 and IL-10. The naïve hamsters when vaccinated with rLdSir2RP alongwith BCG resisted the L. donovani challenge to the tune of ~75% and generated strong IL-12 and IFN-γ mediated Th1 type immune response thereof. The efficacy was further supported by remarkable increase in IgG2 antibody level which is indicative of Th1 type of protective response. Further, with a possible implication in vaccine design against VL, identification of potential T-cell epitopes of rLdSir2RP was done using computational approach. CONCLUSION/SIGNIFICANCE: The immunobiochemical characterization strongly suggest the potential of rLdSir2RP as vaccine candidate against VL and supports the concept of its being effective T-cell stimulatory antigen.

Indexed as

AdultAnimalsComputational BiologyCricetinaeCytokinesHumansImmunizationLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralLymphocyte ActivationMaleMesocricetusNADNitric OxideProtozoan ProteinsCytokinesLeishmaniasis VaccinesNADNitric OxideProtozoan ProteinsSirtuin 2Vaccines, Synthetic

Identifiers

PMID25745863
PMCPMC4351947
OpenAlexW2072968576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.